View in browser

Pharmaceutical Technology

Share this newsletter with a friend or colleague
EC grants approval to BMS’ Opdivo combo for gastroesophageal cancer 

In a Phase III trial, Opdivo plus chemotherapy offered statistically significant improvement in overall survival.


Merck’s molnupiravir: Covid-19 gamechanger status relies on patient risk factors
Molnupiravir access may depend on how risk factors are interpreted but availability could be wider with the help of pharmacists

Pharma’s reliance on horseshoe crabs is threatening the species
Conservationists say using the prehistoric creatures’ blood for bacterial endotoxin testing is no longer justifiable.

Novavax at risk of losing time advantage once Covid-19 vaccine competitors flex production muscle
Competitor protein subunit Covid-19 vaccine manufacturers are slowly closing in at Novavax’s lead.


PTC Therapeutics’ Gene Therapy Manufacturing Centre of Excellence, Hopewell, New Jersey
PTC Therapeutics’ biologics facility will be located within the Bristol-Myers Squibb (BMS) campus in Hopewell, New Jersey.

AstraZeneca API Manufacturing Facility, Dublin, Ireland
AstraZeneca’s API plant will manufacture small molecules for drugs in late-stage development and early marketing.

Moderna Science Centre, Cambridge, Massachusetts
Moderna’s science centre will serve as its new headquarters and support the company’s future research and discoveries.

REACH and RoHS Compliance: Gain a Deeper Understanding

15 Nov - 16 Nov

Online   |  Organiser: Compliance Online


From our partners

Press Releases

Single Use Support Providing Solutions for Gene Therapies
Biopharma solution provider Single Use Support announces an order from Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO).

Pharmapack 2021: Gerresheimer with Innovative SensAIR Platform for a Drug Delivery Device for Biologics
With SensAIR, Gerresheimer presents an innovative platform for on-body drug delivery which can deliver drugs of higher viscosity, such as monoclonal antibodies (mAb). The aim is to provide patients with the best possible support in the subcutaneous delivery of large-volume biologics.

A Novel Analgesic Peptide Drug has Passed its Pre-clinical Research Phase
The pre-clinical research of a new analgesic peptide drug, which is the largest single-funded project in Hainan Province and lasted for five years has finally been completed successfully by the cooperation of the leading organization Hainan University, the Institute of Toxicology and Drugs of the Military Academy of Sciences, and the company GL Biochem (Shanghai) Ltd, who overcame various difficulties and challenges during the five years.


Peptides and Reagents for Peptide Synthesis and Combinatorial Chemistry
GL Biochem (Shanghai) Ltd has an excellent R&D environment with full access to most modern and sophisticated facilities, and equipment necessary for the custom organic or peptide manufacturing.

Scalability Guide – How to Achieve Scalable Freezing & Thawing of Biopharmaceuticals
Scalability around freezing means the ability to guarantee constant stress on proteins (biopharmaceutical molecules) in all scales, filling volumes and loading scenarios.

Challenges in Bulk Drug Substance Logistics
You might think that the final liquid drug substance will be filled into vials at the same location. This is not the case.

Thanks for reading. If you enjoyed this newsletter, please share with colleagues, friends and anybody else, get them to sign up and join the conversation. You can contact us at

Pharmaceutical Technology